Clinical Trial Update: Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update evaluating adjuvant dendritic cell immunotherapy with temozolomide in glioblastoma patients, sponsored by University Hospital Antwerp; cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Dendritic Cell-Immunotherapy
• Temodar (Temozolomide)

Snippet

Sponsor: University Hospital, Antwerp | Conditions: Glioblastoma Multiforme of Brain | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING